Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

3.1%

1 terminated/withdrawn out of 32 trials

Success Rate

96.7%

+10.2% vs industry average

Late-Stage Pipeline

25%

8 trials in Phase 3/4

Results Transparency

0%

0 of 29 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
19(59.4%)
Phase 3
6(18.8%)
Phase 2
5(15.6%)
Phase 4
2(6.3%)
32Total
Phase 1(19)
Phase 3(6)
Phase 2(5)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (32)

Showing 20 of 32 trials
NCT07483398Phase 4Active Not Recruiting

RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease

Role: collaborator

NCT06643078Phase 3Recruiting

A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD

Role: collaborator

NCT04213196Phase 1Completed

Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers

Role: lead

NCT04564872Phase 3Completed

HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Role: lead

NCT04556851Phase 3Completed

HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Role: lead

NCT04540016Phase 1Completed

Mass Balance and Biotransformation of [14C]HSK7653 in Human

Role: lead

NCT03751969Phase 1Withdrawn

A Study Evaluating the Mass Balance of Micro-dose[14C]HSK3486 Emulsion Injection in Healthy Adults

Role: lead

NCT04147416Phase 2Completed

A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation

Role: lead

NCT04110886Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers

Role: lead

NCT04526496Phase 1Completed

Safety, Tolerability and Pharmacokinetics of FTP-198 in Healthy Australian Volunteers

Role: lead

NCT04029766Phase 1Completed

A Study Evaluating Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of HSK3486 Single Bolus Dose Followed With a 30 Minute Constant Infusion in Healthy Male Subjects

Role: lead

NCT04142970Phase 1Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions

Role: lead

NCT04145583Phase 1Completed

A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Voriconazole Tablets

Role: lead

NCT04111159Phase 3Completed

A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Subjects Undergoing Fiberoptic Bronchoscopy

Role: lead

NCT04048811Phase 2Completed

A Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Elective Surgery Patients

Role: lead

NCT04197661Phase 1Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Role: lead

NCT04145596Phase 1Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment

Role: lead

NCT04595916Phase 4Completed

Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury

Role: lead

NCT04556058Phase 1Completed

A Study on the Bioequivalence of Perindopril Tert-butylamine Tablets Taken on an Empty Stomach in Healthy Subjects

Role: lead

NCT04556110Phase 1Completed

A Study on the Bioequivalence of Perindopril Tert-butylamine Tablets Taken on After Meals in Healthy Subjects

Role: lead